These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 29667946

  • 1. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr 23; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract] [Full Text] [Related]

  • 2. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA, Proctor GJ, Stahl SM.
    Clin Schizophr Relat Psychoses; 2018 Jan 23; 11(4):214-220. PubMed ID: 29341821
    [Abstract] [Full Text] [Related]

  • 3. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M, Sung VW.
    Drug Des Devel Ther; 2018 Jan 23; 12():313-319. PubMed ID: 29497277
    [Abstract] [Full Text] [Related]

  • 4. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug 23; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 5. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM.
    Drugs Today (Barc); 2017 Feb 23; 53(2):89-102. PubMed ID: 28387387
    [Abstract] [Full Text] [Related]

  • 6. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N, Jimenez-Shahed J.
    Neurodegener Dis Manag; 2019 Apr 23; 9(2):59-71. PubMed ID: 30702019
    [Abstract] [Full Text] [Related]

  • 7. Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report.
    Palermo G, Mazzucchi S, Unti E, Bonuccelli U, Ceravolo R.
    J Clin Psychopharmacol; 2020 Apr 23; 40(6):628-630. PubMed ID: 33136925
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 23; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 9. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.
    Moondra P, Jimenez-Shahed J.
    Expert Rev Neurother; 2024 Sep 23; 24(9):849-863. PubMed ID: 38982802
    [Abstract] [Full Text] [Related]

  • 10. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May 22; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract] [Full Text] [Related]

  • 11. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug 22; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 12. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F, Luther K, Talreja O.
    Am J Health Syst Pharm; 2020 Jan 24; 77(3):167-174. PubMed ID: 31974564
    [Abstract] [Full Text] [Related]

  • 13. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J, Shi WX, Dashtipour K.
    Pharmacol Ther; 2020 Aug 24; 212():107580. PubMed ID: 32454050
    [Abstract] [Full Text] [Related]

  • 14. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H, Jankovic J.
    Expert Rev Neurother; 2018 Aug 24; 18(8):625-631. PubMed ID: 29996061
    [Abstract] [Full Text] [Related]

  • 15. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L.
    Expert Rev Neurother; 2018 Apr 24; 18(4):323-332. PubMed ID: 29557243
    [Abstract] [Full Text] [Related]

  • 16. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO, Philbin M, Carroll B.
    Expert Opin Pharmacother; 2019 Dec 24; 20(18):2209-2221. PubMed ID: 31613641
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N, Jankovic J.
    Drugs; 2018 Apr 24; 78(5):525-541. PubMed ID: 29484607
    [Abstract] [Full Text] [Related]

  • 18. Valbenazine for Tardive Dyskinesia.
    Freudenreich O, Remington G.
    Clin Schizophr Relat Psychoses; 2017 Apr 24; 11(2):113-119. PubMed ID: 28742396
    [Abstract] [Full Text] [Related]

  • 19. Valbenazine-induced parkinsonism.
    Akbar U, Kim DS, Friedman JH.
    Parkinsonism Relat Disord; 2020 Jan 24; 70():13-14. PubMed ID: 31785443
    [No Abstract] [Full Text] [Related]

  • 20. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec 24; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.